Poziotinib clinical trials
Also written HM781-36B and NOV120101.
Includes 2 studies of Poziotinib hydrochloride.
How each study uses poziotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
21 studies that test it; most in 2017 (3)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 9
Spectrum Pharmaceuticals, Inc (7) · Hanmi Pharmaceutical Company Limited (5) · National OncoVenture (2) · M.D. Anderson Cancer Center (2) · Yonsei University (2) · Seoul National University Hospital (1) · Samsung Medical Center (1) · Korean Association for the Study of Targeted Therapy (1)
Often tested with
Tested in the same studies.
Alpelisib (1) · Nintedanib (1) · Abemaciclib (1) · Tremelimumab (1) · Therapeutic Procedure (1) · Complementary or Alternative Medical Procedure (1)
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses poziotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 21
- A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 MutationsSuspendedPhase 3Spectrum Pharmaceuticals, IncNCT05378763Written as PoziotinibHow we know
- A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibTerminatedPhase 2Spectrum Pharmaceuticals, IncNCT03744715Written as PoziotinibHow we know
- Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedPhase 2Spectrum Pharmaceuticals, IncNCT03318939Written as PoziotinibHow we know
- Poziotinib in EGFR Exon 20 Mutant Advanced NSCLCTerminatedPhase 2M.D. Anderson Cancer CenterNCT03066206Written as PoziotinibHow we know
- A Study of Poziotinib in Patients With Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Activating Mutations in Advanced MalignanciesTerminatedPhase 2Spectrum Pharmaceuticals, IncNCT04172597Written as Poziotinib HydrochlorideHow we know
- Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung CancerWithdrawnPhase 2M.D. Anderson Cancer CenterNCT05045404Written as Poziotinib HydrochlorideHow we know
- Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]CompletedPhase 2Seoul National University HospitalNCT03292250Written as PoziotinibHow we know
- Study of Poziotinib in Participants With HER2-Positive Metastatic Breast CancerCompletedPhase 2Spectrum Pharmaceuticals, IncNCT02659514Written as PoziotinibHow we know
- Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed RegimensCompletedPhase 2Hanmi Pharmaceutical Company LimitedNCT02418689Written as NOV120101 (Poziotinib)How we know
- Study of the Absorption, Metabolism, and Excretion Following a Single Dose of [14C]-Poziotinib in Healthy Male SubjectsCompletedPhase 1Spectrum Pharmaceuticals, IncNCT04436562Written as [14C]-PoziotinibHow we know
- A Study of Poziotinib in Combination With T-DM1 in HER2-Positive Breast CancerTerminatedPhase 1Spectrum Pharmaceuticals, IncNCT03429101Written as PoziotinibHow we know
- Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion MutationTerminatedPhase 2Hanmi Pharmaceutical Company LimitedNCT04044170Written as PoziotinibHow we know
- A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR PathwayCompletedPhase 2Samsung Medical CenterNCT02544997Written as PoziotinibHow we know
- Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing TherapyStatus unknownPhase 2Yonsei UniversityNCT02216916Written as HM781-36BHow we know
- A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)Status unknownPhase 2Yonsei UniversityNCT03770988Written as Treatment with PoziotinibHow we know
- Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)CompletedPhase 2Korean Association for the Study of Targeted TherapyNCT02979821Written as PoziotinibHow we know
- A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric CancerCompletedPhase 1/2Hanmi Pharmaceutical Company LimitedNCT01746771Written as HM781-36B(Poziotinib)How we know
- NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung AdenocarcinomaTerminatedPhase 2National OncoVentureNCT01819428Written as NOV120101 (Poziotinib)How we know
- NOV120101 Phase 2 Study in NSCLC Patients With Aquired Resistance to 1st Generation EGFR Tyrosine Kinase InhibitorsCompletedPhase 2National OncoVentureNCT01718847Written as NOV120101 (Poziotinib)How we know
- Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid TumorsCompletedPhase 1Hanmi Pharmaceutical Company LimitedNCT01455571Written as HM781-36BHow we know
See all 21 studies that test poziotinib →
Given beside what is tested · 1 — poziotinib is usual care or a partner of the new treatment
Codes
What other systems call poziotinib · ClinicalTrials.gg INT005794
- UNII (FDA) OEI6OOU6IKPOZIOTINIBConfirmed FDA, Wikidata
- Wikidata Q27088426poziotinibConfirmed FDA, Wikidata
- NCI Thesaurus C98838PoziotinibOne source FDA
- DrugBank DB12114One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | OEI6OOU6IK | POZIOTINIB | Confirmed FDA, Wikidata |
| Wikidata | Q27088426 | poziotinib | Confirmed FDA, Wikidata |
| NCI Thesaurus | C98838 | Poziotinib | One source FDA |
| DrugBank | DB12114 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.